Nebu-Flow secures additional investment to accelerate next generation respiratory pharmaceuticals

– The company’s nebulizer platform has been developed to provide a number of advantages over existing technologies




GLASGOW, Scotland–(BUSINESS WIRE)–Nebu-Flow has secured an additional $5.9 million of investment to accelerate the next generation of inhaled drugs for patients with respiratory disorders, which are the main cause of death and disability worldwide. The company’s nebulizer platform has been developed to provide a number of advantages over existing technologies. Overall, the worldwide inhalable drug market was valued at approximately $33 billion in 2023, with the nebulizer market valued at over $1 billion.

The funding round was led by SCVC, a leading UK-based venture capital firm that invests in early-stage deep tech spinouts, and was supported by Scottish Enterprise, Foresight WAE Technology, SIS Ventures, Ascension, and Conduit EIS Impact Fund.

Dr Elijah Nazarzadeh, CEO and co-founder of Nebu-Flow, said: “Our mission is to revolutionize respiratory drug delivery. The investment accelerates our development activities to position the company for inhalation delivery of RNA-based formulations. We now look forward to the final product development and commercialization stages, with the support of SCVC and our other investors.”

Dr Elijah Nazarzadeh added: “Essentially, our technology provides new opportunities for targeted drug delivery to the lungs as well as drug delivery to the cardiovascular and central nervous systems. We are engaged with a number of partners in the UK and North America who are currently trialling the product as we prepare for the regulatory approval stage.”

Dr Harry Destecroix, Managing Partner, SCVC, said: “We are deeply impressed by the team’s achievement of its technical and commercial milestones to date, demonstrating their capability and readiness for the next phase in healthcare innovation. This investment underscores our confidence in Nebu-Flow’s groundbreaking nebulisation technology, which is poised to transform respiratory drug delivery, improve health and deliver impact.”

Notes:

– Nebu-Flow was recently awarded a £1m project from Innovate UK, the United Kingdom’s national innovation agency.

– Last year, the former spinout from the University of Glasgow won the Business Start-up Award from the Institute of Physics for “exceptional efforts in the application of surface acoustic waves to a new generation of nebulizers with the potential to transform respiratory drug delivery”.

– Nebu-Flow is featuring at this year’s Respiratory Drug Delivery Conference, RDD 2024, in Tucson, Arizona between 5th-9th May.

– For more information: https://www.nebuflow.com/

Contacts

[email protected]

Subscribe on LinkedIn

Get the free newsletter

Subscribe to MedicaEx for top news, trends & analysis

We're committed to your privacy. MedicaEx uses the information you provide to us to contact you about our relevant content, products, and services. You may unsubscribe from these communications at any time. For more information, check out our Privacy Policy.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Businesswire is solely responsible for the content of the above news submissions. If there are any violations of laws, violations of the membership terms of this website, or the risk of infringing on the rights of third parties, businesswire will be solely responsible for legal and damage compensation. Responsibility has nothing to do with MedicaEx.

Are you in?

Subscribe to receive exclusive content and notifications to your inbox

We're committed to your privacy. MedicaEx uses the information you provide to us to contact you about our relevant content, products, and services. You may unsubscribe from these communications at any time. For more information, check out our Privacy Policy.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.